Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DHP-101, DHP-300, DHP-500 in Dry Eye Syndrome
NCT00788229Phase 2Completed
- Sponsor
- DHP Korea Co., Ltd.
- Start
- Nov 2008
- Primary completion
- Aug 2009
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Aili and carboxymethylcellulose sodium ophthalmic gel in dry eye syndrome (DED) (4 arms), sponsored by DHP Korea Co., Ltd. Primary endpoint: Tear Break Up Time at 12 weeks. Started Nov 2008; status: completed.
02
Drugs
Ailicarboxymethylcellulose sodium ophthalmic gel
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT00788229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788229.